Neil J. Korman MD, PhDProfessor, Department of Dermatology, University Hospitals Cleveland Medical Center; Director, Clinical Trials Unit, and Clinical Director, Murdough Family Center for Psoriasis, University Hospitals Case Medical Center, Cleveland, Ohio
Neil J. Korman, MD, PhD, is a Professor of Dermatology at Case Western Reserve University in Cleveland, Ohio. He is also the director of the Dermatology Clinical Trials Unit in the Department of Dermatology at University Hospitals of Cleveland (UHC). In addition, he serves as the clinical director of the Murdough Family Center for Psoriasis, a comprehensive psoriasis research, education, and treatment program. Dr. Korman earned his medical degree (1984) and doctorate in biomedical engineering (1982) at Case Western Reserve University. His postdoctoral training included a medical internship and dermatology residency at University Hospitals of Cleveland and an immunodermatology fellowship at the National Institutes of Health in Bethesda, Maryland.
Dr. Korman holds subspecialty board certification in dermatological immunology/diagnostic and laboratory immunology. He is a member of the American Dermatologic Association, the Psoriasis Expert Resource Group of the American Academy of Dermatology, an Emeritus Member of the Medical Advisory Board of the National Psoriasis Foundation and a member of the International Pemphigus and Pemphigoid Foundation Medical Board. Dr. Korman is the founding Director of the Regional Center for Immunobullous Diseases.
Dr. Korman has published over 200 articles in the peer-reviewed literature. He has served as an associate editor of Medical and Surgical Dermatology and serves on the editorial board of the Journal of Cutaneous Medicine and Surgery and Psoriasis Forum. He is a reviewer for numerous peer-reviewed journals. Since 1997, he has been the principal or co-principal investigator in more than 100 clinical trials, the majority of which involved psoriasis, including trials of all of the major biologic agents approved for psoriasis and he has also been involved in several translational mechanism of action studies in psoriasis.
Recent Contributions to PracticeUpdate:
- Efficacy and Safety of Dupilumab in the Treatment of Patients With Bullous Pemphigoid
- Long-Term Treatment Outcomes and Safety of Dupilumab in Patients With Bullous Pemphigoid
- Efficacy of Downtitration or Treatment Withdrawal vs Continuous Dosing After Successful Treatment With Baricitinib in Patients With Atopic Dermatitis
- Patient-Reported Adverse Effects Reduced When Switching From Oral to Subcutaneous Methotrexate
- Neutrophil to Lymphocyte Ratio for Predicting Outcomes in Patients With DPP-4 Inhibitor–Associated Bullous Pemphigoid
- Disease Characteristics and Sequence of Skin and Musculoskeletal Disease Onset in Psoriatic Arthritis
- Association of the Psoriatic Microenvironment With Treatment Response
- The Effectiveness of Rituximab in Pemphigus and the Benefit of Additional Maintenance Infusions
- Risk of Anxiety and Depression in Patients With Psoriasis Treated With Apremilast vs Biologics, DMARDs, and Corticosteroids
- Pemphigoid as a Potentially Unrecognized Cause of Pruritus in Nursing Home Residents